Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPACCA: firmonertinib versus investigator's choice of osimertinib or afatinib as first-line treatment for EGFR PACC-mutant advanced NSCLC
CTR20261769Phase 3Active
- Sponsor
- Allist Pharmaceuticals
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of furmonertinib, osimertinib, afatinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started Dec 2025; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261769.